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INTRODUCTION 16
The envelope spike (Env) of the human immunodeficiency virus type 1 (HIV-1) mediates 17 infection of target host cells and is consequently a main target for vaccine design. However, 18
Env displays extreme antigenic diversity, meaning only an immune response of exceptional 19 breadth will be protective (Burton et al., 2012) . Additionally, a dense coat of host derived, 20 immunologically 'self' N-linked glycans shield the underlying protein from host antibody 21 responses (Wei et al., 2003) . In spite of these hurdles, approximately a third of infected 22 individuals develop broadly neutralizing antibody (bnAb) responses against Env after several 23 years of infection (Simek et al., 2009; van Gils et al., 2009 ). 24
While the Env glycan shield typically limits antibody neutralization, many bnAbs 25 have, paradoxically, evolved to recognize epitopes that are either entirely or partially 26 composed of N-linked glycans (Blattner et glycans at four distinct regions of Env: the gp120/gp41 protomer interface (e.g. PGT151), 30 surrounding the CD4 binding site (e.g. HJ16), the V1/V2 loops at the trimer apex (e.g. PG9 31 and PG16), and the oligomannose-type glycans centered around the highly conserved N332 32 site on the outer domain of gp120 (e.g. PGT135 and 2G12) (Crispin et al., 2018) . Given the 33 5 glycan holes, and opening new ones elsewhere on the trimer (Ringe et al., 2019) . This 66 phenomenon is echoed in natural infection, as the glycan shield 'shifts' to escape arising 67 nAbs (Dacheux et al., 2004; Moore et al., 2012; Wagh et al., 2018; Wei et al., 2003) . The 68 N332 glycan, for example, has been observed to shift from the N334 position and back again 69 after the appearance of nAbs (Moore et al., 2012) . While it is accepted that glycan holes offer 70 an immunodominant distraction capable of eliciting autologous nAbs, the extent to which 71 holes hinder the development of bnAbs remains largely unknown. There is evidence to 72 suggest that more complete glycan shields in transmitted/founder viruses correlate with the 73 development of greater neutralization breadth in infected individuals (Wagh et al., 2018) . 74
Future immunization strategies may therefore include immunogens with closed glycan holes, 75 in order to redirect the nAb response away from the immunodominant protein surface toward 76 more broadly neutralizing glycan-based epitopes (McCoy et al., 2016; Ringe et al., 2019) . 77
The elicitation of a bnAb response requires the activation of bnAb precursor B cells. 78
Effective immunogens must therefore be capable of engaging the B cell receptor (i.e. the gl-79 bnAb), prior to affinity maturation of the bnAb in the germinal centers. However, this process 80 is hampered by the low affinity of gl-bnAbs to Env, often due to their inability to 81 accommodate conserved N-linked glycans (Doores et al., 2013; Hoot et al., 2013 ; Ma et al., 82 6 (Behrens and Crispin, 2017). Thus, gp120 displays a significant population of under-91 processed oligomannose-type glycans, termed the intrinsic mannose patch (IMP) (Bonomelli 92 et al., 2011; Doores et al., 2010a ; Go et al., 2013; Pritchard et al., 2015a) . Analysis of 93 recombinant, monomeric gp120 revealed that the removal of individual glycan sites from 94 within the IMP often results in larger-than-expected decreases in the abundance of 95 oligomannose-type glycans, as sites surrounding the deletion become more susceptible to 96 glycan processing (Pritchard et al., 2015a) . In Env trimers displaying native-like 97 conformations, additional steric hindrances imposed by glycan and protein elements from 98 neighboring protomers give rise to a further trimer associated mannose patch (TAMP) 99 oligomannose-type glycans are a conserved feature of the Env glycan shield, and a key bnAb 105 target, in some circumstances they can become susceptible to enzymatic processing. 106 7 maintain the epitope. Furthermore, we show the N334 to N332 escape mutation minimally 116 impacts glycosylation processing. The diverse impact of glycan holes on glycan-dependent 117 bnAbs underscores the role of glycopeptide analysis in vaccine design and the development 118 of new immunogens. 119
RESULTS 120

Enhanced mapping of the 2G12 epitope by cryo-EM 121
To elucidate the molecular details of the 2G12 epitope, we solved a 3.8 Å structure of 2G12 122 Fab 2 bound to BG505 SOSIP.664 by cryo-EM (Figure 1A, Figure S1 , Table S1 ). The two 123 Fab 2 , the glycans at N363 and N386 may also play a role in 2G12 binding by providing 134 support to the N392 glycan via glycan/glycan interactions (Figure S1B) (Sanders et al., 135 2008 ). Previous studies have reported a potential contact between the 2G12 Fab 2 and glycans 136 at positions N137 and N411 (Chuang et al., 2019; Murin et al., 2014) , however, no 137 coordinated density was observed for these glycans in our reconstruction, indicating they do 138 not play a direct structural role in 2G12 binding (Figure S1C) . 139
To further gauge the contribution of individual glycans to the 2G12 epitope, we 140 assessed antibody binding to glycan knockouts by ELISA. As expected, the N295A and 141 N392A deletions resulted in the largest decrease in antibody binding ( Figure 1D) . The 142 N448A and N386A knockouts, while not directly contributing to the 2G12 epitope, 143 diminished binding to a similar extent as a secondary binding site deletion. In contrast, the 9 N411A mutation increased 2G12 binding. Additionally, we sought to determine the impact of 145 filling the nearby 241/289 glycan hole on 2G12 binding. Neither the +N241 or +N289 glycan 146 knock-ins, nor the +N241 N289 double knock-in had a substantial impact on 2G12 binding 147 ( Figure 1C) . 148
Overall resilience of the mannose patches to glycan addition and deletion 149
To assess whether the observed differences in 2G12 binding could be attributed to 150 differences in glycan processing, the glycosylation profiles of the glycan site mutants were 151 compared to that of BG505 SOSIP.664 trimers (Figure 2) . As the removal of glycan sites 152 can conceivably negatively impact trimer integrity, a quaternary structure-dependent antibody 153 (PGT145), targeting a region distal to the site of mutation, was used for purification. The N-154 glycans from the target glycoproteins were enzymatically released, fluorescently labeled, 155 and analyzed by hydrophilic interaction liquid chromatography-ultra performance liquid 156 chromatography (HILIC-UPLC; Figure S3 ). Quantification of oligomannose-type species 157 was performed by the integration of chromatograms before and after digestion with 158 Endoglycosidase H (Endo H; Figure 2B ). Additionally, the oligomannose-type glycans 159 from three biological replicates of BG505 SOSIP.664 were quantified (Figure 2C) , 160 revealing a coefficient of variation of 2.2% for Man 9 GlcNAc 2 and 1.5% for total 161 oligomannose-type glycans. 162
As per BG505 SOSIP.664 trimers, the chromatograms of all the glycan mutants 163 were dominated by oligomannose-type glycans, though the distribution of individual 164 oligomannose-type glycans, particularly Man 9 GlcNAc 2 and Man 8 GlcNAc 2 varied slightly 165 (here referred to as Man9, Man8 etc.) ( Figure S3 ). Previous site-specific glycan analyses 166 of BG505 SOSIP.664 trimers have reported the N295, N332, N339, N386, N392, and 167 N448 sites to be occupied by oligomannose-type glycans, predominantly Man9 (Behrens 168 et al., 2016; Cao et al., 2017) . Accordingly, deletion of each of these sites resulted in a 1 0 decrease in the abundance of both total oligomannose-type glycans and Man9 structures 170 ( Figure 2D ). The largest changes were observed for the N448A and N386A glycan-171 knockouts, which resulted in a 46% and 47% decrease in the abundance of Man9, 172 respectively. Many of the observed decreases were somewhat larger than the decrease 173 predicted upon the loss of a glycan site comprising solely Man9 structure (16%; Figure  174 2B, dashed line). Thus, glycan site deletion on BG505 SOSIP.664 trimers can result in 175 widespread increased glycosylation processing. This effect was not universally observed, 176 for example, the N411A glycan site knockout had minimal impact on overall glycosylation 177 processing despite its location at the center of the IMP (Figure 1 and 2D) . 178
Additionally, we investigated the impact of the N332 to N334 glycan 'shift' escape 179 mutation on glycosylation processing. In contrast to the deletion of the N332 site, the 180 migration of the glycan to the N334 position had negligible impact on either the 181 abundance of Man9, or total oligomannose-type glycans (Figure 2E ). 182
Given that glycan site deletion generally resulted in increased glycosylation 183 processing, and a glycan shift mutation did not impact glycosylation processing, we 184 hypothesized that glycan site addition may restrict processing. Analysis of the +N241 glycan 185 knock-in, however, revealed only a minimal increase in the relative abundance of Man9 186 structures (2%; Figure 2F ). In contrast, the +N289 and +N241 N289 knock-ins resulted in a 187 decrease in both the abundance of oligomannose-type glycans, and Man9 structures. This 188 result may be expected if the knocked-in sites were composed of predominantly complex-189 type glycans. However, the observed decrease in the abundance of Man9 (38% and 48%, 190 respectively) far exceeds the predicted decreases upon the addition of one or two sites 191 containing only complex-type glycans (3% and 7%, respectively; Figure 2F , dashed line). 192
Thus, both glycan site deletions and additions including the N289 site appear to be increasing 193 the glycosylation processing of the trimer.
1
We hypothesized that the BG505 SOSIP.664 trimer may be unaccommodating of 195 the N289 glycan, and that its addition may be inducing conformational changes which in 196 turn influence glycosylation processing. We therefore repeated the analysis of the +N289 197 and +N241 N289 knock-ins on hyperstabilized BG505 SOSIP.v5 trimers (Figure 2A 
Glycan deletion increases mannose trimming throughout the trimer 204
To elucidate the impact of glycan site mutations at the site-specific level, we performed in-205 line liquid chromatography-mass spectrometry (LC-MS) analysis of glycopeptides from the 206 above glycan knockout and knock-in constructs. To aid the assignment of glycopeptides, a 207 glycan library was generated by ion-mobility mass spectrometry analysis of an aliquot of 208 unlabeled N-glycans from the BG505 SOSIP.664 protein ( Figure S4 , Table 1 ). The use of 209 one glycan library for the subsequent analysis of all the glycan site mutants is justified given 210 the likeness of their HILIC-UPLC glycan profiles ( Figure S3 ). The LC-MS methodology has 211 been previously validated (Behrens et al., 2016) . In addition, we performed glycopeptide 212 analysis on three biological replicates of BG505 SOSIP.664 to confirm that observed 213 differences were not due to experimental variation (Figure S5) . 214
The deletion of glycan sites from the network of glycans surrounding the 2G12 215 epitope generally resulted in increased glycosylation processing at the immediately 216 adjacent sites. This was most significant for the N332T, N411A and N448A glycan 217 deletions, surrounding the N295 glycan site. The loss of each of these glycans resulted in a 218 61, 80 and 78 percentage point (pp; the arithmetic difference between two percentages) 1 2 decrease in Man9 at the N295 site, respectively, generally accompanied by a compensatory 220 increase in Man5-8 structures (Figure 3) . The effect was reciprocal, though less 221 pronounced, with the N295A glycan knockout increasing processing at the N332 and N448 222 sites (18 and 37 pp decrease in Man9, respectively; Increased glycosylation processing, however, was not entirely limited to sites adjacent 227 to the glycan knockout. In many instances, glycan site deletion resulted in increased 228 processing emanating from the point of knockout. For example, the N332T knockout also 229 increased processing at the N448 and N339 sites (40 and 13 pp decrease, respectively; 230 
Differential effects of glycan additions on processing 240
In line with high glycan density limiting mannosidase trimming, glycopeptide analysis of the 241 glycan knock-in constructs revealed that the +N241 glycan site addition restricted processing 242 at the neighboring N448 site, resulting in a 21 pp increase in the abundance of Man9 ( Figure 1 3
In contrast, the +N289 site knock-in resulted in increased glycosylation processing, 245 both at sites neighboring the introduced glycan and throughout the trimer. The N262, N295 246 and N332 sites all displayed a decrease in the abundance of Man9 (37, 20, 28 pp decrease, 247 respectively; Figure 4) . The N363 and N234 sites were also affected to a similar extent, 248 despite their greater distance from the +N289 knock-in. The +N241 N289 double glycan 249 knock-in displayed both restricted glycosylation processing at the N448 site (12 pp increase 250 in Man9), and increased processing at the N262, N295, N332 and N363 sites (Figure 4) . 251
The increased glycan processing associated with the +N289 glycan knock-in is 252 surprising, given that high glycan density is generally associated with restricted glycosylation 253 processing. We had hypothesized that the BG505 SOSIP.664 protein might be unable to 254 accommodate a glycan at this site, and thus the addition of a glycan may be causing wider 255 conformational changes to the protein. We therefore investigated the impact of these glycan 256 knock-ins on the hyperstabilized SOSIP.v5 background (Torrents de la Pena et al., 2017) 257 (Figure 2A) . In line with the HILIC-UPLC analysis, glycopeptide analysis confirmed that the 258 addition of the N289 glycan to the BG505 SOSIP.v5 background resulted in increased glycan 259 processing, though to a slightly less extent than that observed on the SOSIP.664 background 260 ( Figure 4D) . The SOSIP.v5 +N241 N289 double glycan knock-in also exhibited changes in 261 processing similar to that of the SOSIP.664 background, but not as pronounced. 262
We had considered that the decrease in the total abundance of oligomannose-type 263 glycans observed by HILIC-UPLC analysis may be, at least partially, explained by the 264 addition of a site(s) comprising predominantly complex-type glycans. However, the precise 265 compositions of the N241 and N289 glycan additions could not be readily determined as they 266 co-occupy peptides with the N234 and N295 sites, respectively. To classify the glycan-type 267 occupying these sites, we subjected the glycopeptides to sequential digests with Endo H (to with previous reports, the N197A glycan knockout also reduced antibody binding (Behrens et 287 al., 2016) . Given that the N197 glycan does not contribute to either antibody epitope, we 288 hypothesized that the knockout may be disrupting glycosylation processing at the epitope and 289 performed glycopeptide analysis to address this. 290
Removal of either the N156 or N197 glycan sites resulted in increased processing at 291 the proximal N160 site (Figure 5A and C) . This was particularly true of the N156A glycan 292 knockout, which resulted in the complete processing of Man9 to smaller oligomannose-type 293 structures and complex-type glycosylation, such that the dominant peak shifted from Man9 to The contribution of glycans to many bnAb epitopes has been defined by structural 323 methods, such as X-ray crystallography and cryo-EM, complemented by glycopeptide 324 analysis (Crispin et al., 2018; Ward and Wilson, 2017) . In this study, we present the highest 1 7 resolution structure reported to date of 2G12 in complex with its Env target. We confirm that 326 2G12 directly contacts the oligomannose-type glycans at four sites and reveal the 327 contributions of the surrounding glycans. It has previously been shown that mutations 328 affecting glycan sites lying outside of bnAb epitopes can disrupt binding and/or neutralization 329 with this, we reported that the deletion of glycan sites in the networks surrounding glycan-331 dependent antibody epitopes perturbed antibody binding, in some cases to the same extent as 332 mutations directly impacting the epitope. Such observations may be partially explained by 333 disruptions to the fine processing of the glycan epitope upon the mutation of proximal glycan 334 sites, specifically increased trimming by mannosidases. 335
Despite causing significant disruption to the fine processing of the 2G12 epitope, the 336 N411A knockout displayed increased 2G12 binding, consistent with previous reports 337 (Scanlan et al., 2002) . The N411 glycan was unresolved in the cryo-EM structure, though the 338 asparagine residue occupied the middle of 2G12-glycan complex (Figure S1) . A glycan at 339 this site could potentially result in a clash or the entropy of the glycan could be reduced upon 340 2G12 binding (Figure 1) . 341
The current study was restricted to the analysis of soluble BG505 SOSIP.664 342 immunogens, an important experimental model for viral glycosylation. We note that soluble 343 SOSIP.664 trimers display somewhat elevated oligomannose levels compared to virion-344 It is not yet known the extent to which a successful vaccine candidate must display 389 precise glycan epitopes. However, the results presented here shed light on the role of 390 individual glycan sites in the fine processing of bnAb epitopes. We reveal the hierarchical 391 role of glycan networks in stabilizing the structure and fine processing of two key bnAb 392 epitopes, the trimer apex and intrinsic mannose patch. A growing understanding of the factors 393 shaping the glycosylation of Env will aid the continued development of HIV-1 immunogens. (Figure S5) shaking. The cells were transfected at a density of 1x10 6 cells per mL and incubated for 476 5 days at 37°C with 8% CO 2 and 125 rpm shaking. 477
METHOD DETAILS 478
BG505 SOSIP.664 and SOSIP.v5 construct design 479
Asparagine residues within the N295, N339, N386, N392, N411 and N448 consensus 480 sequence, N-X-S/T (where X ≠ P), were mutated to alanine. For the N332 site, we reverted 481 the asparagine to threonine, as per the parental BG505 sequence. To introduce N-linked 482 glycan sites at the N241 and N289 sites, the serine at the 241 position was mutated to 483 asparagine, and/or the proline at the 291 position was mutated to serine. Mutants were 484 created using the QuikChange II site-directed mutagenesis kit (Agilent), as per the 485 manufacturer's instructions. 486
Expression and purification of proteins 487 BG505 SOSIP.664 and SOSIP.v5 proteins were transiently (co-)expressed in HEK 293F cells 488 with a Furin expression plasmid at a ratio of (4:1). BG505 SOSIP.664 and SOSIP.v5 proteins 489 were purified using either 2G12, PGT145, or PGT151 affinity chromatography, as previously 490 described (Sanders et al., 2013) . Comparisons were only drawn between BG505 SOSIP.664 PGV04 Fab and 2G12, PGT145, PGT151, PG16 and PG9 IgG were produced by co-493 expression of the heavy and light chain genes in HEK293F cells. PGV04 Fab was purified 494 using KappaSelect and Mono-S columns (GE Healthcare). 2G12, PGT145, PGT151, PG16 495 and PG9 IgG were purified with a Protein A column (GE Healthcare). 2G12 Fab 2 was 496 prepared by digesting 2G12 IgG with papain using a previously described protocol (Calarese 497 et al., 2003) . Microscopy Sciences, Protochips, Inc.) which had been plasma cleaned for 5 seconds using a 507 mixture of Ar/O 2 (Gatan Solarus 950 Plasma system). The sampled was manually blotted off, 508 and then immediately plunged into liquid ethane using a manual freeze plunger. 509
Movies were collected via the Leginon interface on a FEI Titan Krios operating at 300 510 keV mounted with a Gatan K2 direct electron detector (Carragher et al., 2000) . Each movie 511 was collected in counting mode at 22,500 × nominal magnification resulting in a calibrated 512 pixel size of 1.31 Å/pix at the object level. A dose rate of ~10 e -/(pix*s) was used; exposure 513 time was 200 ms per frame. The data collection resulted in a total of 2,184 movies containing 514 50 frames each. Total dose per movie was 76 e -/Å 2 . Data were collected with a defocus range 515 of -1.5 to -3.0 microns. Movies were imported into cryoSPARC v2 and frames were aligned 2 8 (CTF) for each aligned micrograph was estimated using Gctf (Zhang, 2016). The HIV Env 518 portion of PDB 5ACO was converted to an EM density and low pass filtered to 40 Å using 519 pdb2mrc and subsequently used as a template for particle picking within cryoSPARC v2 (Lee  520   et for 16 h at 37 °C. The reactions were dried and glycopeptides were extracted using C18 Zip-592 tip (Merck Millipore) following the manufacturer's protocol. 593
Liquid chromatography-mass spectrometry analysis of glycopeptides 594
Eluted glycopeptides were dried again and re-suspended in 0.1% formic acid prior to mass 595 spectrometry analysis. An aliquot of glycopeptides was analyzed by LC-MS with an Easy-596 nLC 1200 system coupled to an Orbitrap Fusion mass spectrometer (Thermo Fisher 597 Scientific) using higher energy collisional dissociation (HCD) fragmentation. Peptides were 598 separated using an EasySpray PepMap RSLC C18 column (75 μ m x 75 cm) with a 599 275 minute linear gradient consisting of 0%-32% acetonitrile in 0.1% formic acid over 600 240 minutes followed by 35 minutes of 80% acetonitrile in 0.1% formic acid. The flow rate 601 was set to 200 nL/min. The spray voltage was set to 2.8 kV and the temperature of the heated 602 capillary was set to 275 °C. HCD collision energy was set to 50%, appropriate for 603 fragmentation of glycopeptide ions. Glycopeptide fragmentation data were extracted from the 604 raw file using Byonic™ (Version 2.7) and Byologic™ software (Version 2.3; Protein Metrics 605 Inc.). The glycopeptide fragmentation data were evaluated manually for each glycopeptide; 606 the peptide was scored as true-positive when the correct b and y fragment ions were observed 607 along with oxonium ions corresponding to the glycan identified. The relative abundance of 608 each glycoform at each site was calculated using the extracted ion chromatograms for true-609 positive peptides. 610
Site-specific glycan classification 611
Remaining glycopeptides were first digested with Endo H to cleave oligomannose-and 612 hybrid-type glycans, leaving a single GlcNAc residue at the corresponding site. The reaction 613 mixture was then dried completely and resuspended in a mixture containing 50 mM 614 ammonium bicarbonate and PNGase F using only O 18 -labeled water (Sigma-Aldrich) 3 2
GlcNAc residues intact. The use of H 2 O 18 in this reaction enables complex glycan sites to be 617 differentiated from unoccupied glycan sites as the hydrolysis of the glycosidic bond by 618 PNGase F leaves an O 18 isotope on the resulting aspartic acid residue. The resultant peptides 619 were purified by C18 ZipTip, as outlined above, and subjected to LC-MS in a similar manner 620 to before, but using a lower HCD energy of 27% as glycan fragmentation was not required. 621
Data analysis was performed as above. 622
ELISAs 623
Antibody 2G12 was expressed in HEK 293F cells (1:2 ratio of heavy to light chain 624 plasmids) and purified by Protein A affinity chromatography according to the 625 manufacturer's instructions (GE Healthcare). High binding 96 well assay plates (Corning) 626
were incubated with BG505 SOSIP.664 proteins (10 ug/mL in PBS) overnight at 4 °C. 627
Plates were washed with a solution of PBS containing 0.5% Tween 20 (v/v) and blocked 628 for 1h at RT with 5% milk in PBS + 0.5% Tween. After another wash step, the primary 629 antibody was incubated (1:2 dilution series with a starting concentration of 20 ug/mL) in 630 PBS for 1h at RT. Plates were washed and an anti-human IgG conjugated to Horseradish 631 Peroxidase (Abcam) secondary antibody was added at a 1:2'000 dilution in PBS. Plates 632 were washed and TMB substrate solution (Thermo Fisher Scientific) was added. The 633 reaction was stopped with sulfuric acid after 5 min and the OD 450 nm was measured. 634
QUANTIFICATION AND STATISTICAL ANALYSIS 635
The integration of peaks corresponding to fluorescently labeled N-glycans was performed 636 using Empower 3.0 (Waters, Manchester, UK) (Figure 2 and S3) . The IM-MS data used to 637 generate the glycan library were acquired and processed with MassLynx v4.1 and Driftscope 638 version 2.8 software (Waters, Manchester, UK) ( Figure S4 ). Chromatographic areas were 639 extracted for site-specific analysis using Byonic™ (Version 2.7) and Byologic™ software 
